Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 26, Issue 27, 2008, Pages 4473-4479

  Robinson, K Sue ^a   Williams, Michael E ^a   van Der Jagt, Richard H ^a   Cohen, Philip ^a   Herst, Jordan A ^a   Tulpule, Anil ^a   Schwartzberg, Lee S ^a   Lemieux, Bernard ^a   Cheson, Bruce D ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; BENDAMUSTINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; COMPARTMENT SYNDROME; CONSTIPATION; COUGHING; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DIVERTICULITIS; DRUG DOSE REDUCTION; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HUMAN; INFECTION; INJECTION SITE REACTION; INSOMNIA; LEUKOPENIA; LIVER TOXICITY; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OROPHARYNX CANDIDIASIS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT INFECTION; SEPSIS; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GASTROINTESTINAL DISEASES; HEADACHE; HEMATOLOGIC DISEASES; HUMANS; INFECTION; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, B-CELL; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NAUSEA; NEOPLASM RECURRENCE, LOCAL; NITROGEN MUSTARD COMPOUNDS; REMISSION INDUCTION;

EID: 52649177173     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.0001     Document Type: Article

References (25)

1. American Cancer Society: Cancer Facts and Figures 2008. Atlanta, GA, American Cancer Society, 2008
2. Schulz H, Bohlius JF, Trelle S, et al: Immuno chemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. J Natl Cancer Inst 99:706-714, 2007
3. Friedberg JW, Huang J, Dillon H, et al: Initial therapeutic strategy in follicular lymphoma (FL): An analysis from the National LymphoCare Study (NLCS). J Clin Oncol 24:428s, 2006 (suppl, abstr 7527)
4. Fisher RI, Leblanc M, Press OW, et al: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:8447-8452, 2005
5. Hainsworth JD, Litchy S, Shaffer DW, et al: Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23:1088-1095, 2005
6. Williams ME, Densmore JJ: Biology and therapy of mantle cell lymphoma. Curr Opin Oncol 17:425-431, 2005
7. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas, Version 3, 2008. http://www.nccn.org/ professionals/physician_gls/PDF/nhl.pdf
8. Strumberg D, Harstrick A, Doll K, et al: Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7:415-421, 1996
9. Leoni LM, Bailey B, Reifert J, et al: Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14:309-317, 2008
10. Friedberg JW, Cohen P, Chen L, et al: Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study. J Clin Oncol 26:204-210, 2008
11. Chow KU, Sommerlad WD, Boehrer S, et al: Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases. Haematologica 87:33-43, 2002
12. Alas S, Emmanouilides C, Bonavida B: Inhibition of interleukin 10 by rituximab results in downregulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7:709-723, 2001
13. National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0, 2003. http://ctep.cancer.gov/reporting/ctc.html
14. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
15. Rummel MJ, Al-Batran SE, Kim SZ, et al: Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23:3383-3389, 2005
16. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
17. Brookmeyer R, Crowley J: A confidence interval for the median survival time. Biometrics 39:29-41, 2007
18. Weide R, Pandorf A, Heymanns J, et al: Bendamustine/mitoxantrone/ rituximab (BMR): A very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies - Final results of a pilot study. Leuk Lymphoma 45:2445-2449, 2004
19. Witzig TE, Flinn IW, Gordon LI, et al: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-3269, 2002
20. Horning SJ, Younes A, Jain V, et al: Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23:712-719, 2005
21. Van Oers MH, Klasa R, Marcus RE, et al: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-3301, 2006
22. Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064-3071, 2004
23. Rummel MJ, von Grunhagen U, Niederle N, et al: Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas: First interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 110:385, 2007 (abstr)
24. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005
25. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005